Literature DB >> 9647364

Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter.

S D Patil1, L Y Ngo, P Glue, J D Unadkat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9647364     DOI： 10.1023/a:1011945103455

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  13 in total

1.  Sodium-dependent nucleoside transport in the human intestinal brush-border membrane.

Authors:  S D Patil; J D Unadkat
Journal:  Am J Physiol       Date:  1997-06

2.  Functional expression of human intestinal Na+-dependent and Na+-independent nucleoside transporters in Xenopus laevis oocytes.

Authors:  G Chandrasena; R Giltay; S D Patil; A Bakken; J D Unadkat
Journal:  Biochem Pharmacol       Date:  1997-06-15       Impact factor: 5.858

Review 3.  Nucleoside and nucleobase transport systems of mammalian cells.

Authors:  D A Griffith; S M Jarvis
Journal:  Biochim Biophys Acta       Date:  1996-10-29

4.  Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. Two transport systems with differing substrate specificities.

Authors:  D Vijayalakshmi; J A Belt
Journal:  J Biol Chem       Date:  1988-12-25       Impact factor: 5.157

5.  Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus.

Authors:  J J Lertora; A B Rege; J T Lacour; N Ferencz; W J George; R B VanDyke; K C Agrawal; N E Hyslop
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

Review 6.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

7.  Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro.

Authors:  F Kawana; S Shigeta; E De Clercq
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

8.  Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.

Authors:  R Paroni; M Del Puppo; C Borghi; C R Sirtori; M Galli Kienle
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-06

Review 9.  Ribavirin: a clinical overview.

Authors:  H Fernandez; G Banks; R Smith
Journal:  Eur J Epidemiol       Date:  1986-03       Impact factor: 8.082

10.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875
View more
  23 in total

1.  Bile acids alter the subcellular localization of CNT2 (concentrative nucleoside cotransporter) and increase CNT2-related transport activity in liver parenchymal cells.

Authors:  Sonia Fernández-Veledo; Isabel Huber-Ruano; Ivette Aymerich; Sylvie Duflot; F Javier Casado; Marçal Pastor-Anglada
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

2.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

3.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 4.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

Review 5.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.

Authors:  M Homma; A L Jayewardene; J Gambertoglio; F Aweeka
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

Authors:  S L Preston; G L Drusano; P Glue; J Nash; S K Gupta; P McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.

Authors:  Hidetsugu Saito; Shinichiro Tada; Hirotoshi Ebinuma; Hiromasa Ishii; Kazuo Kashiwazaki; Masahiko Takahashi; Nobuhiro Tsukada; Jiro Nishida; Shin Tanaka; Hiroshi Shiozaki; Toshifumi Hibi
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

9.  The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.

Authors:  Christopher J Endres; Aaron M Moss; Rajgopal Govindarajan; Doo-Sup Choi; Jashvant D Unadkat
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

Review 10.  The concentrative nucleoside transporter family, SLC28.

Authors:  Jennifer H Gray; Ryan P Owen; Kathleen M Giacomini
Journal:  Pflugers Arch       Date:  2003-07-11       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.